Q2 2025 Medipharm Labs Corp Earnings Call Transcript
Key Points
- MediPharm Labs Corp (MEDIF) reported a 14% year-over-year increase in revenue, driven by a 50% growth in international medical cannabis sales.
- The company successfully defended against a costly proxy contest, maintaining shareholder support and alignment with its long-term vision.
- MediPharm Labs Corp (MEDIF) ended Q2 with CAD10.4 million in cash, up from CAD8.4 million in Q1, despite incurring CAD2.2 million in proxy-related expenses.
- The company is virtually debt-free and owns its production facilities outright, providing a strong financial position.
- MediPharm Labs Corp (MEDIF) is actively pursuing international expansion, with significant growth opportunities in markets like Germany, Australia, and the UK.
- The proxy contest incurred significant legal and advisory fees, totaling CAD2.2 million, which temporarily diverted focus from strategic initiatives.
- Gross profit margin declined to 28% due to product mix challenges, particularly in the international market.
- Adjusted EBITDA for Q2 was negative CAD0.6 million, reflecting margin dilution from product mix.
- Canadian medical cannabis revenue declined slightly by CAD0.1 million from Q1 2025.
- The company faces ongoing challenges in achieving consistent profitability, with a need to balance cost reductions and revenue growth.
Thank you for standing by, and welcome to the MediPharm Labs conference call to discuss the second quarter 2025 results. Our speakers on today's call are David Pidduck, President and Chief Executive Officer; and Greg Hunter, Chief Financial Officer.
[Operator Instructions] The information contained on this presentation should be considered together with the more detailed information, disclosure, financial data and statements available on the company's website and on SEDAR plus profile.
As seen on Slide 2 and 3, I would like to note that this earnings call contains forward-looking information and is based on the company's current expectations, estimates and beliefs as of today's date, and we'll also use terms that are non-IFRS financial measures.
Please review the company's most recent disclosure material for the risks associated with the use of forward-looking information and the use of non-IFRS financial measures in this presentation. Please note that all dollar amounts mentioned in today's call are in Canadian dollars, unless otherwise noted. And now I would like to turn the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
